Abstract:BACKGROUND: Matrix metalloproteinase-2 (MMP-2) is well known for its critical role in cell survival and cancer development. It also plays an important role in hematopoietic recovery after chemotherapy-induced myelosuppression. In this study, the authors investigated the association of MMP-2 polymorphisms with treatment efficacy and the occurrence of severe toxicity in patients with nonsmall cell lung cancer (NSCLC) who were receiving first-line, platinum-based chemotherapy. METHODS: A pharmacogenetic association study was performed in 663 Chinese patients who had inoperable stage III/IV NSCLC and were receiving first-line, platinum-based regimens. Information about objective response, progression-free survival, overall survival, grade 3 or 4 gastrointestinal toxicity (nausea/vomiting), and hematologic toxicity (neutropenia, anemia, thrombocytopenia) was available. Sixteen tag single nucleotide polymorphisms (SNPs) of MMP-2 were assessed. RESULTS: In 7 polymorphisms, significant associations were observed with the incidence of grade 3 or 4 neutropenia. The variant homozygotes of reference SNP rs12934241 exhibited the most significant effect on the risk of neutropenia, leading to an incidence rate that increased from 12.3% (for the C/C genotype) to 50% (for the T/T genotype; odds ratio, 8.33; P = 8.8 x 10(-5)). Stratified analyses indicated that rs12934241 exhibited a much stronger influence in the cisplatin-gemcitabine regimen subgroup than subgroups that received other regimens (Pinteraction = .003). Further haplotype analyses produced results that were consistent with results from single-SNP analyses. However, no significant association was observed between MMP-2 polymorphisms and treatment efficacy, including response rate, clinical benefit, progression-free survival, and overall survival. CONCLUSIONS: To the authors' knowledge, this study provides the first evidence for a predictive role of MMP-2 polymorphisms in the variability of severe chemotherapy-related neutropenia among Chinese patients with platinum-treated, advanced NSCLC. Cancer 2012;35873598. (C) 2011 American Cancer Society.

Functional Polymorphisms of Matrix Metalloproteinase-9 and Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy

[The Correlation Between Polymorphisms of Matrix Metalloproteinase-2 and -9 Genes and Colorectal Cancer of Chinese Patients].

Association of Matrix Metalloproteinase‐2 and ‐9 Promoter Polymorphisms with Colorectal Cancer in Chinese

MMP-9 Expression in Peripheral Blood Mononuclear Cells and the Association with Clinicopathological Features and Prognosis of Nasopharyngeal Carcinoma

Matrix Metalloproteinase-2 Polymorphisms and Clinical Outcome of Chinese Patients with Nonsmall Cell Lung Cancer Treated with First-Line, Platinum-Based Chemotherapy

Functional Polymorphisms of Matrix Metalloproteinase-9 Are Associated with Risk of Occurrence and Metastasis of Lung Cancer

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy

Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma.

Functional polymorphisms and haplotypes in the promoter of the<i>MMP2</i>gene are associated with risk of nasopharyngeal carcinoma

Impact of Matrix Metalloproteinase-8 Polymorphisms on Nasopharyngeal Carcinoma Risk

Association of Matrix Metalloproteinase-9 Genotypes With Nasopharyngeal Carcinoma Risk

Association of Matrix Metalloproteinase-9 Gene Polymorphism with Gastric Cancer in Guangdong Province

Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma

The MMP-7-181A/G Gene Polymorphism is a Prognostic Indicator in Patients with Gastric Cancer

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Locoregionally Advanced Nasopharyngeal Carcinoma

Relationship between MMP9 gene polymorphisms and genetic susceptibility in nasopharyngeal carcinoma

Prognostic Value of Matrix Metalloproteinase 9 Expression in Patients with Non-Small Cell Lung Cancer

Genetic Polymorphisms of Long Non-Coding RNA GAS5 Predict Platinum-Based Concurrent Chemoradiotherapy Response in Nasopharyngeal Carcinoma Patients

Polymorphisms in the MMP1 and MMP3 Promoter and Non-Small Cell Lung Carcinoma in North China.

Impact of Polymorphisms in Angiogenesis-Related Genes on Clinical Outcomes of Radiotherapy in Patients with Nasopharyngeal Carcinoma.

ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma.